Galectin Therapeutics (NASDAQ: GALT $3.80) GALT is our number 1 stock pick for August, 2018. After a fundamental analysis we conclude the scientific data is credible & compelling, GALT is … [Read more...] about GALT is Strong Buy: Oversold and Cancer Catalyst Imminent
*80% Of Biotech
Companies Fail
Companies Fail
*90% Of Traders
Lose Money
*100% DON'T
Have To
At MS Money Moves we leverage our teams expertise in science, business, and technical analysis identifying gainful biotech trades.
How we do it?
Patience, Discipline, Objective Analysis.
See our performance record for more info.
Try it for free, Let's get it!
